• Leukemia
• Chronic Lymphocytic Leukemia

Dr. David Maloney develops new treatments for patients with lymphomas, leukemias and myeloma as well as other cancers. He is widely recognized as an expert in treating people with these cancers. The focus of his laboratory and clinical research is immunotherapies, which are treatments that can enhance anti-cancer immune responses. One strategy uses immune cell products known as antibodies. Dr. Maloney was instrumental in the development and testing of rituximab, the first antibody-based cancer drug on the market. This drug has transformed the treatment of certain leukemias and lymphomas. Dr. Maloney also is developing genetically engineered immune cell therapies, which are called CAR T-cell therapies, for various cancers. He is the first medical director for cellular immunotherapy at Fred Hutch and the Bezos Family Immunotherapy Clinic at Fred Hutchinson Cancer Center, where these strategies are being used to treat patients.